MIB-626 for COVID-19: real-time analysis

Download Image

Post

c19early.org

MIB-626 for COVID-19

1 study with 39 patients

Serious outcome risk

MIB-626

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 MIB-626 studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−156%

Mortality (1)−156%

RCTs (1)−156%

Late (1)−156%

00.511.5+

← MIB-626
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

MIB-626 is an oral formulation of β-nicotinamide mononucleotide (NMN), a small molecule NAD+ precursor that may restore host NAD+ levels depleted during SARS-CoV-2 infection.


Jun 18 2025	Pencina et al., FASEB BioAdvances, doi:10.1096/fba.2025-00014	Oral MIB‐626 (β Nicotinamide Mononucleotide) Safely Raises Blood Nicotinamide Adenine Dinucleotide Levels in Hospitalized Patients With COVID‐19 and Acute Kidney Injury: A Randomized Controlled Trial
Jun 18 2025	156% higher mortality (p=1) and 18% improved recovery (p=0.71). RCT 42 hospitalized patients with COVID-19 and acute kidney injury (AKI) showing no clinical benefit with MIB-626 (β-nicotinamide mononucleotide) treatment. The study found that 1.0g of MIB-626 twice daily safely and significantly raised ..